VTRS
Updated: 24/09/2026, 02:08:31
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.
Revenue
$14.3B
FY 2025 · Reported
Net income
$-3.5B
FY 2025 · Reported
Gross margin
34.8%
FY 2025 · Calculated
Free cash flow
$1.9B
FY 2025 · Calculated
R&D intensity
N/A
FY — · Reported
Share repurchases
$0.5B
FY 2025 · Reported
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Viatris overview
Global healthcare company, ~1 billion patients/year, >165 countries, >30,000 employees, 27 sites, >1,400 approved molecules
“The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules”
Reportable segments
Four reportable segments: Developed Markets, Greater China, JANZ, Emerging Markets
“Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets.”
U.S. customer concentration
U.S. customer base: small number of very large firms; scale in R&D, supply chain and portfolio breadth positions Viatris to serve them
“While Viatris' U.S. customer base is extensive, it comprises a small number of very large firms as the pharmaceutical industry has undergone tremendous change and consolidation.”
Channel types
Channels: wholesalers/distributors, retailers, institutional pharmacies, mail-order/e-commerce, specialty pharmacies, OTC retail
“Pharmaceutical wholesalers/distributors purchase prescription medicines and other medical products directly from manufacturers for storage in warehouses and distribution centers.”
Innovative pipeline Phase 3 readouts
Five positive Phase 3 readouts (EFFEXOR Japan, MR-107A-02, contraceptive patch, MR-142, MR-141); sotagliflozin UAE launch; US Iron Sucrose launch
“The Company advanced its innovative pipeline with five positive Phase 3 data readouts”
Developed Markets significant products
Key DM products: Lyrica, Lipitor, Creon, Breyna, Influvac, Wixela Inhub, EpiPen, Fraxiparine, Yupelri; new launches in US and Europe
“Significant products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Breyna™, Influvac®, Wixela Inhub®, EpiPen® Auto-Injector, Fraxiparine®, and Yupelri®.”
Greater China significant products
Greater China: branded LOE products incl. Lipitor, Norvasc, Viagra; expanded retail pharmacy and e-commerce channels amid VBP
“Significant products within the Greater China segment include Lipitor®, Norvasc®, and Viagra®.”
JANZ innovative pipeline assets
JANZ: National Health Insurance price regulation; wholesale distribution; pipeline EFFEXOR GAD, Nefecon, pitolisant
“In Japan, the National Health Insurance regulates the pricing of pharmaceutical products to healthcare providers.”
Manufacturing footprint
27 manufacturing, packaging and distribution sites; global centers in Pittsburgh, Shanghai, Hyderabad
“The Company has 27 manufacturing, packaging, and distribution sites worldwide”
Aculys Pharma acquisition
Oct 2025 acquisition of Aculys Pharma: pitolisant rights in Japan; Spydia Nasal Spray rights in Japan and certain APAC markets
“including its October 2025 acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions primarily in Japan.”
Selatogrel and cenerimod development programs
Acquired development programs for selatogrel and cenerimod, both in Phase 3; enrollment on track
“our acquisition of the development programs for selatogrel and cenerimod, which are currently in Phase 3 development”
Recent divestitures
Divestitures: biosimilars to Biocon Biologics (2022), women's health to Insud Pharma (2024), India API to Matrix Pharma (2024), OTC to Cooper Consumer Health (2024), Duphaston/Femoston to Theramex (2023), Upjohn Distributor Markets rights (2023-24)
“In July 2024, the Company completed the divestiture of its OTC Business to Cooper Consumer Health, a leading European OTC drug manufacturer and distributor.”
Market types and country examples
Prescription: US brand, China, Turkey, Poland, Mexico; Substitution: France, Italy, Spain, Portugal, Japan, Australia; Tender: NZ, Sweden, South Africa, Germany; Distribution: US generics, UK, Norway
“Examples of countries served by Viatris that are mainly tender markets are New Zealand, Sweden, South Africa, as well as Germany.”
2025 financial and capital return highlights
2025 revenues $14.30B despite divestitures and Indore Impact; >$1B capital returned ($500M buybacks, $561M dividends); $2.94B goodwill impairment
“Viatris reported 2025 total revenues of $14.30 billion, despite the impact of divestitures and the Indore Impact”
Biocon Biologics stake and settlement
~12.9% CCPS stake in Biocon Biologics ($815.0M at YE2025 vs $1,349.8M YE2024); $60.0M pre-tax settlement loss Q4 2024
“the Company recorded a pre-tax loss of $60.0 million as a component of Other Expense (Income), Net in the consolidated statements of operations during the fourth quarter of 2024.”
Manufacturing and supplier concentration
Limited number of manufacturing facilities; third-party suppliers produce substantial portion of API and products
“We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process.”
Impairment charges
Goodwill impairment charge of $2.94 billion in 2025; future impairment risk
“including a goodwill impairment charge of $2.94 billion in 2025”
Tariffs and trade restrictions
Tariffs, trade restrictions, domestic sourcing requirements and retaliation are a material strategic risk
“The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business”
Loss of exclusivity example
May lose market exclusivity for Amitiza 24 μg in Japan in June 2026
“we may lose market exclusivity for Amitiza® 24 μg in Japan in June 2026”
Significant indebtedness
Significant indebtedness; refinancing risk at potentially higher interest rates
“We have significant indebtedness, which could lead to adverse consequences or adversely affect our financial position and prevent us from fulfilling our obligations under such indebtedness, and any refinancing of this debt could be at significantly higher interest rates.”
Indore facility remediation
Substantial progress on initial remediation at Indore, India oral finished dose facility; ongoing FDA engagement
“Viatris made substantial progress on its initial remediation activities at its oral finished dose manufacturing facility in Indore, India”
Currency fluctuations
Currency fluctuations have impacted and could continue to adversely affect results
“Currency fluctuations and changes in exchange rates have impacted and could continue to adversely affect our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price.”
A limited number of manufacturing facilities and third-party suppliers produce a substantial portion of API and products, some requiring highly exacting and complex processes.
“We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products”
New product launches are an important growth driver in Developed Markets, including iron sucrose injection, octreotide acetate in the U.S., and pomalidomide, dapagliflozin, atorvastatin/ezetimibe, rivaroxaban, ferric carboxymaltose in Europe.
“New product launches are an important growth driver. Important recent launches include iron sucrose injection and octreotide acetate for injectable suspension in the U.S.”
Tariffs, trade restrictions or domestic sourcing requirements, and retaliatory actions in territories where Viatris, partners, suppliers or customers operate could materially adversely affect the business.
“The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business”
Currency fluctuations and exchange rate changes have impacted and could continue to adversely affect business, cash flows, dividends, buybacks and stock price.
“Currency fluctuations and changes in exchange rates have impacted and could continue to adversely affect our business, financial condition, results of operations, cash flows”
Healthcare consumerism, increased spending power and demand for premium medical products have driven strong growth in retail pharmacy and e-commerce channels in China, partially absorbing hospital channel VBP reductions.
“Healthcare consumerism, increased spending power, and demand for premium medical products have generated strong growth in these new channels and partially absorbed the reductions seen in the hospital channel due to VBP.”
Viatris has significant indebtedness; refinancing could be at significantly higher interest rates, affecting its financial position and obligations.
“We have significant indebtedness, which could lead to adverse consequences or adversely affect our financial position and prevent us from fulfilling our obligations under such indebtedness, and any refinancing of this debt could be at significantly higher interest rates.”
Viatris is increasingly dependent on IT and information systems, which face cybersecurity and data leakage risks; ML/AI incorporation may result in legal and regulatory risks.
“We are increasingly dependent on IT and information systems and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.”
See which prediction-market events move VTRS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Zacks Investment Research • STOCK • 19/05/2026, 14:41:09
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 18/05/2026, 12:50:16
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 18:00:56
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)
Seeking Alpha • STOCK • 12/05/2026, 06:54:00
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
Zacks Investment Research • STOCK • 07/05/2026, 16:41:16
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 16:21:18
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
Zacks Investment Research • STOCK • 07/05/2026, 12:31:33
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research • STOCK • 07/05/2026, 11:55:51
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research • STOCK • 05/05/2026, 16:20:17
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
PRNewsWire • STOCK • 10/04/2026, 08:59:00
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
Seeking Alpha • STOCK • 25/03/2026, 20:15:57
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
Zacks Investment Research • STOCK • 26/02/2026, 13:46:31
